Bomyntra: Uses, Dosage & Side Effects
A monoclonal antibody targeting RANK ligand to prevent skeletal complications from bone metastases and treat giant cell tumor of bone
Bomyntra (denosumab) is a fully human monoclonal antibody that targets RANK ligand (RANKL), a key mediator of bone destruction. By blocking RANKL, Bomyntra inhibits the formation, function, and survival of osteoclasts – the cells responsible for breaking down bone. This medication is primarily used in adults with advanced cancer to prevent serious skeletal complications caused by bone metastases, such as pathological fractures, spinal cord compression, and the need for radiation therapy or surgery to the bone. Bomyntra is also approved for the treatment of giant cell tumor of bone (GCTB) that cannot be surgically removed or where surgery is not the optimal approach. It is administered as a subcutaneous injection every four weeks and requires a prescription. Bomyntra is a biosimilar to the reference product XGEVA and is marketed by Fresenius Kabi.
Quick Facts: Bomyntra
Key Takeaways
- Bomyntra (denosumab 120 mg) is a fully human monoclonal antibody that blocks RANK ligand to inhibit osteoclast-mediated bone destruction, thereby preventing skeletal-related events in patients with advanced cancer that has spread to the bones.
- It is also approved for the treatment of giant cell tumor of bone (GCTB) in adults and skeletally mature adolescents when surgical resection is not feasible or when surgery would result in severe morbidity.
- All patients receiving Bomyntra must take calcium and vitamin D supplements (unless they have hypercalcemia) because denosumab can cause significant hypocalcemia, which may lead to muscle spasms, seizures, and cardiac rhythm disturbances.
- A dental examination is recommended before starting treatment, as osteonecrosis of the jaw (ONJ) is a recognized adverse effect, particularly in patients receiving concurrent chemotherapy, corticosteroids, or angiogenesis inhibitors.
- Bomyntra is administered as a subcutaneous injection of 120 mg every 4 weeks; for giant cell tumor of bone, additional loading doses are given on days 8 and 15 of the first month of treatment.
What Is Bomyntra and What Is It Used For?
Bomyntra contains denosumab, a fully human immunoglobulin G2 (IgG2) monoclonal antibody produced in genetically engineered Chinese hamster ovary (CHO) cells. The drug targets and binds with high affinity and specificity to receptor activator of nuclear factor kappa-B ligand (RANKL), a transmembrane or soluble protein that belongs to the tumor necrosis factor (TNF) superfamily. RANKL is a critical mediator of bone remodeling and plays a central role in the pathophysiology of bone destruction associated with cancer.
Under normal physiological conditions, bone undergoes continuous remodeling through a tightly regulated balance between bone formation by osteoblasts and bone resorption by osteoclasts. RANKL, produced by osteoblasts and other cells within the bone microenvironment, binds to its receptor RANK on the surface of osteoclast precursors and mature osteoclasts, stimulating their differentiation, activation, and survival. Osteoprotegerin (OPG), a decoy receptor also produced by osteoblasts, normally counterbalances RANKL by binding to it and preventing its interaction with RANK. When cancer cells metastasize to bone, they disrupt this delicate balance by directly or indirectly increasing RANKL production, leading to excessive osteoclast activity and accelerated bone destruction.
Denosumab mimics the action of osteoprotegerin by binding RANKL with very high affinity, thereby preventing RANKL from interacting with RANK on osteoclasts and their precursors. This effectively inhibits osteoclast formation, function, and survival, leading to a rapid and profound reduction in bone resorption. Within 24 hours of a single subcutaneous dose, markers of bone resorption (such as urinary N-telopeptide of type I collagen and serum C-telopeptide) decrease dramatically, with maximal suppression achieved within approximately one month.
Bomyntra is a biosimilar medicinal product, meaning it has been shown to be highly similar to the reference product XGEVA (denosumab, Amgen) in terms of quality, safety, and efficacy. The European Medicines Agency (EMA) approved Bomyntra based on a comprehensive comparability exercise that included analytical, non-clinical, and clinical studies demonstrating biosimilarity. Being a biosimilar, Bomyntra provides the same clinical benefits as the reference product and offers patients and healthcare systems an additional treatment option.
Indications
Bomyntra is used in the following clinical settings, as approved by regulatory authorities including the EMA:
- Prevention of skeletal-related events in adults with advanced cancer involving bone: When cancer spreads to the bones (bone metastases), it can cause severe and debilitating complications known as skeletal-related events (SREs). These include pathological fractures (bones that break because they have been weakened by cancer), spinal cord compression (when cancer in the spine presses on the spinal cord, potentially causing paralysis), and the need for radiation therapy or surgery to the bone. Clinical trials, including the pivotal phase III studies comparing denosumab with zoledronic acid, demonstrated that denosumab was superior in delaying the time to first SRE in patients with solid tumors (such as breast cancer and prostate cancer) metastatic to bone, and was non-inferior in patients with other solid tumors or multiple myeloma.
- Treatment of giant cell tumor of bone (GCTB): GCTB is a locally aggressive, benign bone tumor that is characterized by the presence of multinucleated giant cells that are essentially osteoclasts. These giant cells express RANK, while the stromal cells of the tumor produce excessive RANKL, driving the recruitment, maturation, and bone-destructive activity of the giant cells. By blocking RANKL, denosumab eliminates the giant cells from the tumor, inhibits tumor-induced osteolysis, and promotes the formation of new bone. Bomyntra is indicated for adults and skeletally mature adolescents with GCTB that is unresectable (cannot be removed surgically) or where surgical resection is likely to result in severe morbidity (such as limb amputation or significant functional impairment).
The RANK/RANKL/OPG pathway is the central regulatory system for osteoclast biology. By precisely targeting RANKL, denosumab effectively acts as a molecular shield that prevents the activation and survival of bone-destroying osteoclasts. Unlike bisphosphonates, which are incorporated into bone matrix and work by poisoning osteoclasts that have already begun resorbing bone, denosumab works upstream by preventing osteoclast maturation and activation in the first place. This mechanism leads to more complete and sustained suppression of bone resorption.
Other denosumab-containing products include Prolia (denosumab 60 mg), which is indicated for the treatment of osteoporosis and bone loss, and the reference product XGEVA (denosumab 120 mg). Additional biosimilars include Ponlimsi, Junod, Osvyrti, Enwylma, Jubbonti, and ZADENVI. It is essential not to use Bomyntra simultaneously with other denosumab-containing products, as this would result in a duplicate dose and increase the risk of side effects.
What Should You Know Before Using Bomyntra?
Contraindications
There are specific situations in which Bomyntra must not be used. These absolute contraindications must be identified and addressed before treatment begins:
- Hypersensitivity: Do not use Bomyntra if you are allergic to denosumab or any of the excipients in the product, including acetic acid, sodium acetate trihydrate, sorbitol, polysorbate 20, or water for injections. Allergic reactions, including rare cases of anaphylaxis, have been reported with denosumab.
- Severe untreated hypocalcemia: Bomyntra must not be started in patients with severely low calcium levels in the blood that have not been corrected. Because denosumab profoundly suppresses bone resorption (a process that releases calcium into the blood), initiating treatment in a patient who already has low calcium can precipitate life-threatening hypocalcemia.
- Unhealed lesions from dental or oral surgery: Treatment should not begin if the patient has unhealed wounds in the mouth following dental or oral surgical procedures, due to the increased risk of osteonecrosis of the jaw.
Warnings and Precautions
Tell your doctor immediately if you experience muscle spasms, twitching, or cramps; numbness or tingling in your fingers, toes, or around your mouth; seizures; confusion; or loss of consciousness while taking Bomyntra. These may be signs of dangerously low calcium levels in your blood, which can also cause an abnormal heart rhythm (prolonged QT interval) detectable on an electrocardiogram (ECG).
Before and during treatment with Bomyntra, your doctor should be aware of the following important safety considerations:
- Calcium and vitamin D supplementation: All patients receiving Bomyntra must take calcium and vitamin D supplements unless they have high blood calcium levels (hypercalcemia). If your blood calcium is low, your doctor may prescribe calcium supplementation before starting Bomyntra. Your calcium levels will be monitored regularly through blood tests, particularly before each dose and within the first two weeks of starting treatment.
- Kidney impairment: Patients with severe kidney problems, kidney failure, or those requiring dialysis are at increased risk of developing hypocalcemia, especially if they are not taking calcium supplements. Kidney function should be assessed before and periodically during treatment, and calcium monitoring should be more frequent in these patients.
- Osteonecrosis of the jaw (ONJ): This serious side effect involves damage to the jawbone and has been reported in patients receiving denosumab injections for cancer-related conditions. ONJ can cause persistent pain, non-healing sores or ulcers in the mouth, and loosening of teeth. It can be difficult to treat once established. To reduce the risk, you should undergo a dental examination before starting Bomyntra, maintain excellent oral hygiene throughout treatment, attend regular dental check-ups, and ensure your dentures fit properly. If you need any dental work, inform both your doctor and dentist that you are receiving Bomyntra. Seek immediate medical attention if you develop mouth or jaw problems.
- Atypical femoral fractures: Unusual fractures of the thigh bone (femur) have been reported in patients treated with denosumab. These fractures can occur with minimal or no trauma and may be preceded by a dull, aching pain in the thigh, hip, or groin area. Contact your doctor if you experience any new or unusual pain in these areas.
- Hypercalcemia after discontinuation in GCTB patients: Patients with giant cell tumor of bone who stop taking Bomyntra may develop high blood calcium levels (hypercalcemia) in the weeks to months following treatment discontinuation. Your doctor will monitor you for signs and symptoms of hypercalcemia after you stop treatment, including nausea, vomiting, excessive thirst, frequent urination, confusion, and constipation.
Risk factors that increase the likelihood of developing osteonecrosis of the jaw include concurrent chemotherapy, radiation therapy, corticosteroid use, anti-angiogenic therapy, poor oral hygiene, pre-existing dental disease, invasive dental procedures during treatment, ill-fitting dentures, and smoking. Patients with multiple risk factors should be monitored especially closely.
Pregnancy and Breastfeeding
Bomyntra has not been studied in pregnant women. Based on its mechanism of action and the role of RANKL in normal fetal development, denosumab may cause harm to the developing fetus. Animal studies have shown adverse effects on bone development, the immune system, and the lymphatic system in offspring exposed to RANKL inhibitors during pregnancy. It is strongly recommended that Bomyntra should not be used during pregnancy.
Women of childbearing potential should use highly effective contraception during treatment with Bomyntra and for at least 5 months after the last dose. If you become pregnant during treatment or within 5 months of the last dose, inform your doctor immediately so that appropriate monitoring and care can be arranged.
It is not known whether denosumab is excreted in human breast milk. Because many antibodies are secreted in milk and the potential for harm to the nursing infant has not been established, a decision must be made whether to discontinue breastfeeding or discontinue Bomyntra, taking into account the importance of the drug to the mother. If you are breastfeeding during treatment, tell your doctor.
Children and Adolescents
Bomyntra is not recommended for children and adolescents under 18 years of age, with the exception of adolescents with giant cell tumor of bone whose skeletons have finished growing (skeletal maturity). The use of denosumab has not been studied in children and adolescents with cancers that have spread to the bone, and the impact of RANKL inhibition on the growing skeleton could potentially affect normal bone development and growth plate function.
Driving and Operating Machinery
Bomyntra has no or negligible effect on the ability to drive and use machines. However, if you experience side effects such as dizziness or fatigue, you should exercise caution when driving or operating machinery until these symptoms resolve.
Important Information About Excipients
Each vial of Bomyntra contains 78 mg of sorbitol (E420). Patients with hereditary fructose intolerance should not receive this medicine unless strictly necessary. Bomyntra also contains less than 1 mmol (23 mg) of sodium per 120 mg dose, meaning it is essentially sodium-free. Additionally, it contains 0.17 mg of polysorbate 20 (E432) per vial, which can cause allergic reactions in some individuals. Inform your doctor if you have any known allergies to these substances.
How Does Bomyntra Interact with Other Drugs?
Unlike small-molecule drugs that are metabolized by cytochrome P450 (CYP) enzymes in the liver, denosumab is a large protein (monoclonal antibody) that is cleared from the body primarily through the reticuloendothelial system via intracellular catabolism. This means that traditional drug-drug interactions involving liver metabolism are not expected with Bomyntra. However, there are important considerations regarding concurrent use with other bone-active agents.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other denosumab products (Prolia, XGEVA, biosimilars) | Duplicate dosing; excessive RANKL inhibition and increased risk of hypocalcemia and ONJ | Absolute contraindication – never use simultaneously |
| Bisphosphonates (zoledronic acid, alendronate, etc.) | Additive suppression of bone resorption; increased risk of hypocalcemia, ONJ, and atypical femoral fractures | Should not be used concurrently; no established benefit of combination |
Other Considerations
| Drug / Category | Consideration | Recommendation |
|---|---|---|
| Corticosteroids | Concurrent use may increase the risk of ONJ and infections; corticosteroids also lower calcium | Monitor closely; ensure adequate calcium/vitamin D supplementation |
| Angiogenesis inhibitors (bevacizumab, sunitinib, etc.) | May increase the risk of osteonecrosis of the jaw when used concurrently with denosumab | Increased ONJ surveillance; dental assessment before and during treatment |
| Immunosuppressants | RANKL plays a role in immune function; combined immunosuppression may increase infection risk | Monitor for signs of infection |
| Calcium-lowering drugs (calcitonin, cinacalcet) | Additive risk of hypocalcemia when combined with denosumab | Frequent calcium monitoring; dose adjustments may be needed |
Always inform your doctor about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. While denosumab does not have traditional pharmacokinetic drug interactions, the combined effects with other bone-active or immunomodulatory agents can have important clinical consequences.
In clinical trials, denosumab was used concomitantly with a wide range of anticancer therapies – including chemotherapy, hormonal therapy, and targeted agents – without evidence of pharmacokinetic interactions. The co-administration with standard cancer treatments did not alter the pharmacodynamic effects of denosumab on bone turnover markers.
What Is the Correct Dosage of Bomyntra?
Bomyntra is administered exclusively by or under the supervision of a healthcare professional. It is given as a subcutaneous injection (under the skin), typically into the thigh, abdomen, or upper arm. The injection should never be given intravenously or intramuscularly. Before administration, the vial should be allowed to reach room temperature (up to 25°C) to minimize discomfort at the injection site. The solution should be visually inspected and must be clear, colorless to slightly yellow, and free from visible particles. Cloudy or discolored solution should not be used. A 27-gauge needle is recommended for administration.
Adults – Bone Metastases
Standard Dosage for Skeletal-Related Event Prevention
Dose: 120 mg subcutaneously every 4 weeks (approximately monthly)
Duration: Treatment continues for as long as the patient derives clinical benefit, as determined by the treating physician in consultation with the patient
Supplementation: Calcium (at least 500 mg) and vitamin D (at least 400 IU) daily, unless hypercalcemia is present
In the pivotal phase III clinical trials, patients received denosumab 120 mg subcutaneously every 4 weeks alongside daily calcium and vitamin D supplementation. This dosing regimen demonstrated superiority or non-inferiority to zoledronic acid (4 mg IV every 3–4 weeks) for the prevention of skeletal-related events across multiple tumor types, including breast cancer, prostate cancer, and other solid tumors with bone metastases.
Adults and Skeletally Mature Adolescents – Giant Cell Tumor of Bone
Dosage for Giant Cell Tumor of Bone (GCTB)
Loading phase: 120 mg subcutaneously on day 1, day 8, and day 15 (three doses in the first month)
Maintenance phase: 120 mg subcutaneously every 4 weeks thereafter
Duration: Treatment is continued as long as clinically indicated. The optimal duration has not been established.
Supplementation: Calcium and vitamin D daily, unless hypercalcemia is present
The additional loading doses during the first month are designed to achieve rapid suppression of osteoclast activity and RANKL-driven bone destruction in the tumor. In clinical studies of patients with GCTB, denosumab treatment led to elimination of giant cells from tumor tissue in the vast majority of patients, with corresponding clinical improvements including reduced pain and improved functional status.
Children
Bomyntra is not recommended for use in children under 18 years of age, except for skeletally mature adolescents with giant cell tumor of bone. The safety and efficacy of denosumab in the pediatric population for other indications have not been established. Because RANKL plays an important role in bone growth and development, inhibiting RANKL during the period of skeletal growth could potentially affect bone modeling, growth plate function, and tooth development.
Elderly Patients
No dose adjustment is required for elderly patients. In clinical trials, denosumab was studied in a substantial proportion of patients over 65 years of age, and no clinically meaningful differences in safety or efficacy were observed compared to younger adults. However, elderly patients may be at increased risk of hypocalcemia due to age-related decline in kidney function, reduced dietary calcium intake, and lower vitamin D levels. Careful monitoring of calcium and vitamin D status is particularly important in this population.
Renal and Hepatic Impairment
No dose adjustment is required for patients with renal impairment, including those on dialysis. However, patients with severe renal impairment (creatinine clearance <30 mL/min) or those receiving dialysis are at significantly greater risk of developing severe hypocalcemia. Calcium levels should be monitored more frequently in these patients. No dose adjustment is needed for patients with hepatic impairment, as monoclonal antibodies are not metabolized by the liver.
Missed Dose
If a dose of Bomyntra is missed, the injection should be administered as soon as possible. Thereafter, injections should be scheduled every 4 weeks from the date of the last injection. Missing doses may allow skeletal-related events to occur, so adherence to the dosing schedule is important. Contact your doctor or nurse to reschedule your appointment if you are unable to attend on the planned date.
Overdose
There is no specific antidote for denosumab overdose. In clinical trials, doses up to 180 mg every 4 weeks and single doses up to 3 mg/kg intravenously have been administered without additional safety concerns beyond those observed at the recommended dose. In the event of overdose, patients should be monitored for signs and symptoms of hypocalcemia and treated with supportive measures including calcium and vitamin D supplementation as needed.
What Are the Side Effects of Bomyntra?
Like all medicines, Bomyntra can cause side effects, although not every patient experiences them. The side effects listed below are based on the known safety profile of denosumab 120 mg from extensive clinical trial data and post-marketing surveillance. The frequency categories used below follow international conventions:
Contact your doctor immediately if you experience: muscle spasms, twitching or cramps, numbness or tingling in fingers, toes, or around the mouth, seizures, confusion, or loss of consciousness (signs of hypocalcemia); persistent mouth or jaw pain, swelling, non-healing sores, or loose teeth (signs of osteonecrosis of the jaw); or new or unusual pain in the hip, groin, or thigh (possible atypical femoral fracture).
Very Common
May affect more than 1 in 10 people
- Musculoskeletal pain (bone pain, joint pain, or muscle pain), which can sometimes be severe
- Shortness of breath (dyspnea)
- Diarrhea
Common
May affect up to 1 in 10 people
- Low blood phosphate levels (hypophosphatemia)
- Tooth extraction
- Excessive sweating (hyperhidrosis)
- Development of a new type of cancer (in patients with advanced malignancy)
Uncommon
May affect up to 1 in 100 people
- High blood calcium (hypercalcemia) after stopping treatment in patients with giant cell tumor of bone
- New or unusual pain in the hip, groin, or thigh (may be an early sign of an atypical femoral fracture)
- Lichenoid drug eruptions (rash that may appear on the skin or as sores in the mouth)
Rare
May affect up to 1 in 1,000 people
- Allergic reactions (anaphylaxis) – wheezing or difficulty breathing, swelling of the face, lips, tongue, throat, or other body parts, rash, itching, or hives. In rare cases, these reactions may be severe and life-threatening.
Not Known
Frequency cannot be estimated from available data
- Ear pain, ear discharge, or ear infection – these may be signs of bone damage in the ear (osteonecrosis of the external auditory canal)
Hypocalcemia in Detail
Low blood calcium (hypocalcemia) is a pharmacologically predictable effect of RANKL inhibition. Because bone resorption releases calcium into the bloodstream, profoundly suppressing this process with denosumab reduces the body’s ability to maintain normal calcium levels through this mechanism. In clinical trials with denosumab 120 mg, hypocalcemia of any grade occurred in up to 9.6% of patients with solid tumors and bone metastases. Severe hypocalcemia (grade 3–4) was reported in approximately 3.1% of patients.
The risk of hypocalcemia is highest in the first few weeks of treatment and in patients with pre-existing factors such as renal impairment, inadequate calcium intake, low vitamin D levels, or concurrent use of other medications that can lower calcium. Symptoms can range from mild (tingling, muscle cramps) to life-threatening (seizures, cardiac arrhythmias including QT prolongation, cardiac arrest). This is why calcium and vitamin D supplementation and monitoring are mandatory for all patients receiving Bomyntra.
Osteonecrosis of the Jaw (ONJ)
ONJ is a well-recognized complication of anti-resorptive therapy, including denosumab. It is characterized by exposed or dead jawbone that fails to heal, typically occurring after dental procedures such as tooth extraction. In clinical trials and post-marketing reports, the incidence of ONJ with denosumab 120 mg ranges from approximately 1% to 5%, with higher rates observed with longer duration of treatment and in patients with additional risk factors.
The pathophysiology of ONJ is not fully understood but is thought to involve the combination of suppressed bone turnover in the jaw (which has a high rate of normal bone remodeling), reduced blood supply, local trauma from dental procedures or ill-fitting dentures, and potential infection. Preventive dental care before and during treatment, along with avoidance of invasive dental procedures when possible, is the cornerstone of ONJ risk management.
Reporting Side Effects
If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report suspected side effects directly to your national adverse drug reaction reporting system. Reporting helps provide more information on the safety of this medicine and allows continuous monitoring of its benefit-risk balance.
How Should You Store Bomyntra?
Proper storage of Bomyntra is essential to maintain the stability and effectiveness of the medication. As a biological product containing a monoclonal antibody, denosumab is sensitive to extreme temperatures, freezing, vigorous shaking, and excessive light exposure. Improper storage can lead to protein denaturation and loss of efficacy.
- Refrigeration: Store Bomyntra in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not place the vial in the freezer compartment.
- Do not freeze: Freezing can damage the protein structure of denosumab and render the product ineffective. If the vial has been frozen, do not use it.
- Light protection: Keep the vial in its original outer carton to protect from light throughout storage.
- Room temperature use: Before injection, the vial may be allowed to reach room temperature (up to 25°C / 77°F) to make the injection more comfortable. Once brought to room temperature, Bomyntra must be used within 30 days. Do not return it to the refrigerator after it has reached room temperature.
- Do not shake: The vial must not be shaken, as vigorous agitation can cause protein aggregation and foaming, potentially affecting the quality of the product.
- Expiration: Do not use Bomyntra after the expiry date printed on the label and carton (marked EXP). The expiry date refers to the last day of the stated month.
- Disposal: Each vial is for single use only. Any unused solution should not be re-used. Do not dispose of medicines in household waste or wastewater. Ask your pharmacist about safe disposal methods.
For healthcare professionals: before administration, visually inspect the Bomyntra solution. It should be a clear, colorless to slightly yellow liquid, free from visible particles. Do not inject the solution if it appears cloudy, discolored, or contains particulate matter. The entire contents of the vial should be withdrawn and administered. Inject slowly to minimize discomfort at the injection site.
What Does Bomyntra Contain?
Understanding the composition of Bomyntra is important for patients and healthcare professionals, particularly to identify any ingredients to which a patient may be allergic or intolerant.
| Component | Role | Amount per Vial |
|---|---|---|
| Denosumab | Active ingredient (monoclonal antibody) | 120 mg in 1.7 mL (70 mg/mL) |
| Acetic acid | Buffer (pH adjustment) | See SmPC |
| Sodium acetate trihydrate | Buffer (pH stabilization) | See SmPC |
| Sorbitol (E420) | Tonicity agent / stabilizer | 78 mg |
| Polysorbate 20 (E432) | Surfactant (prevents protein aggregation) | 0.17 mg (0.10 mg/mL) |
| Water for injections | Solvent | To 1.7 mL |
Bomyntra is supplied as a clear, colorless to slightly yellow solution for injection, free from visible particles. It is available as single-use vials in pack sizes of 1, 3, or 4 vials. Not all pack sizes may be marketed in every country.
The marketing authorization holder is Fresenius Kabi Deutschland GmbH, Else-Kroener-Strasse 1, 61352 Bad Homburg von der Hoehe, Germany. The manufacturer is Fresenius Kabi Austria GmbH, Hafnerstrasse 36, 8055 Graz, Austria.
Bomyntra is a biosimilar to the reference medicinal product XGEVA (denosumab, Amgen). Biosimilars are biological medicines that are highly similar to an already authorized biological medicine (the reference product). They are approved based on a comprehensive comparability exercise that demonstrates equivalent quality, safety, and efficacy. Switching between the reference product and its biosimilar, under appropriate medical supervision, is considered safe and effective based on current regulatory guidance.
Frequently Asked Questions About Bomyntra
Both Bomyntra and Prolia contain denosumab as the active ingredient, but they are approved for different conditions and use different doses. Bomyntra contains 120 mg of denosumab per vial and is used for the prevention of skeletal-related events in adults with bone metastases from solid tumors and for the treatment of giant cell tumor of bone. It is administered every 4 weeks. Prolia contains 60 mg of denosumab in a pre-filled syringe and is primarily used for the treatment of osteoporosis (in postmenopausal women and men at increased risk of fractures) and for the treatment of bone loss associated with hormone ablation therapy. Prolia is administered every 6 months. These products should never be used together.
The duration of Bomyntra treatment depends on the condition being treated and the individual patient’s response. For the prevention of skeletal-related events in patients with bone metastases, treatment is typically continued for as long as the patient is benefiting from therapy and the cancer is being managed. For giant cell tumor of bone, the optimal duration has not been definitively established, but clinical studies have included patients treated for extended periods. Your oncologist will regularly assess whether continued treatment is appropriate based on your clinical status, disease progression, and overall health.
It is important to discuss any planned dental procedures with both your oncologist and your dentist before proceeding. Routine dental care, including cleaning and fillings, is generally acceptable and in fact encouraged to maintain good oral health. However, invasive dental procedures such as tooth extractions, dental implants, or oral surgery should be avoided if possible during treatment, as these significantly increase the risk of osteonecrosis of the jaw (ONJ). If an invasive dental procedure is absolutely necessary, your medical team will evaluate the risks and may temporarily adjust your treatment schedule. Always inform your dentist that you are receiving Bomyntra.
When you stop taking Bomyntra, the effects on bone resorption are reversible. Within approximately 6 months after the last dose, markers of bone resorption return to pre-treatment levels. For patients with bone metastases, stopping treatment may allow the resumption of skeletal-related events. For patients with giant cell tumor of bone, stopping treatment may be associated with tumor recurrence and, importantly, there is a risk of rebound hypercalcemia (high blood calcium) in the weeks to months after discontinuation. Your doctor will monitor your calcium levels carefully after stopping treatment and will discuss the implications of discontinuation with you.
Bomyntra is a biosimilar of XGEVA. This means Bomyntra has been proven to be highly similar to XGEVA in terms of its molecular structure, biological activity, clinical efficacy, and safety profile. Both products contain denosumab 120 mg and are used for the same indications. The EMA approved Bomyntra based on a rigorous comparability exercise. While they are made by different manufacturers (Bomyntra by Fresenius Kabi, XGEVA by Amgen), they are considered therapeutically equivalent and interchangeable under appropriate medical supervision.
The 120 mg vial formulation of Bomyntra (used for bone metastases and GCTB) is intended to be administered by a healthcare professional in a clinical setting. This allows for proper monitoring of the patient, correct injection technique, and immediate management of any adverse reactions. Unlike the 60 mg pre-filled syringe formulation (Prolia), which some patients may self-inject at home for osteoporosis, the 120 mg oncology dose typically requires professional administration in a hospital or clinic.
References
- European Medicines Agency (EMA). Bomyntra – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822. doi:10.1016/S0140-6736(10)62344-6
- Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139. doi:10.1200/JCO.2010.29.7101
- Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275-280. doi:10.1016/S1470-2045(10)70010-3
- Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone (RECONSTRUCT): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2019;20(12):1719-1729. doi:10.1016/S1470-2045(19)30578-1
- Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650-1663. doi:10.1016/j.annonc.2020.07.019
- U.S. Food and Drug Administration (FDA). XGEVA (denosumab) – Prescribing Information. Last updated 2024. Available at: www.fda.gov
- World Health Organization (WHO). Model List of Essential Medicines. 23rd edition, 2023. Available at: www.who.int
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. doi:10.1002/jbmr.2405
- Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132. doi:10.1200/JCO.2010.31.3304
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Oncology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following EMA, FDA, and WHO guidelines
Evidence Standard
Level 1A – Based on systematic reviews and randomized controlled trials (GRADE framework)
Editorial Independence
No pharmaceutical company funding or advertising. Fully independent medical editorial content.
Last medical review: | Next scheduled review: